We have more than a decade of experience contending with some of the world’s most devastating diseases, including COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS. Hard-won lessons and significant advances illustrate that our proven technology has tremendous potential to make a substantial contribution to public health worldwide.

Our vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.

We are also developing proprietary immune-stimulating saponin-based adjuvants at Novavax AB, our wholly owned Swedish subsidiary. Matrix-M™ has been shown to enhance immune responses and has been well tolerated in multiple clinical trials.

Request for proposal (RFP) overview

Novavax announces projects that are open for competitive bidding.

Novavax is developing NVX-CoV2373, a new vaccine for SARS-CoV-2, in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). To rapidly advance the program and deliver experimental vaccine doses as soon as possible, Novavax is requesting proposals for multiple projects.

For a list of open requests for proposal or if you would like instructions on how to participate in an RFP issued by Novavax, download our RFP Information Document.

John Trizzino, CBO & CFO, speaks of NVAX work on a coronavirus vaccine with Ariane Datil of WUSA9. - Video